Pharmacia
This article was originally published in The Gray Sheet
Executive Summary
FDA approves company's CeeOn Edge 911A intraocular lens April 16 for patients whose cataractous lens has been surgically removed. A 434-patient, 15-center clinical trial evaluating the CeeOn Edge showed a low incidence of posterior capsular opacification due to the square-edged design of the lens, Pharmacia says. Of 320 patients who completed one-year follow-up, 97% achieved visual acuity of 20/40 or better